Oncaspar (Enzon Inc)

Oncaspar (Enzon Inc) - General Information

Pegylated L-asparagine amidohydrolase from E. coli. Pegylation substantially (by a factor of 4) extends the protein half life.


Pharmacology of Oncaspar (Enzon Inc)

In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Oncaspar exploits a metabolic defect in asparagine synthesis of some malignant cells.


Oncaspar (Enzon Inc) for patients


Oncaspar (Enzon Inc) Interactions

Unfavorable interactions of L-asparaginase with some antitumor agents have been demonstrated. 1 It is recommended, therefore, that ONCASPAR� be used in combination regimens only by physicians familiar with the benefits and risks of a given regimen. Depletion of serum proteins by ONCASPAR� may increase the toxicity of other drugs which are protein bound. Additionally, during the period of its inhibition of protein synthesis and cell replication, ONCASPAR� may interfere with the action of drugs such as methotrexate, which require cell replication for their lethal effects. ONCASPAR� may interfere with the enzymatic detoxification of other drugs, particularly in the liver. Physicians using a given treatment regimen should be thoroughly familiar with its benefits and risks.

Imbalances in coagulation factors have been noted with the use of ONCASPAR� predisposing to bleeding and/or thrombosis. Caution should be used when administering any concurrent anticoagulant therapy, such as coumadin, heparin, dipyridamole, aspirin, or non-steroidal anti-inflammatories.


Oncaspar (Enzon Inc) Contraindications

ONCASPAR� is contraindicated in patients with pancreatitis or a history of pancreatitis. ONCASPAR� is contraindicated in patients who have had significant hemorrhagic events associated with prior L-asparaginase therapy. ONCASPAR� is also contraindicated in patients who have had previous serious allergic reactions, such as generalized urticaria, bronchospasm, laryngeal edema, hypotension, or other unacceptable adverse reactions to ONCASPAR�.


Additional information about Oncaspar (Enzon Inc)

Oncaspar (Enzon Inc) Indication: For treatment of acute lymphoblastic leukemia
Mechanism Of Action: Oncaspar (Enzon Inc), more effective than asparaginase, converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Pegaspargase
Synonyms: L-asparagine amidohydrolase; Putative L-asparaginase precursor
Drug Category: Antineoplastic Agents
Drug Type: Biotech; Approved; Investigational

Other Brand Names containing Pegaspargase: Oncaspar (Enzon Inc);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Oncaspar (Enzon Inc): Injection, solution Intramuscular
Injection, solution Intravenous
Chemical IUPAC Name: Pegylated E. coli L-asparagine amidohydrolase
Chemical Formula: C1377H2208N382O442S17
Pegaspargase on Wikipedia:
Organisms Affected: Humans and other mammals